"Nootropic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.
| Descriptor ID |
D018697
|
| MeSH Number(s) |
D27.505.954.427.637
|
| Concept/Terms |
Nootropic Agents- Nootropic Agents
- Agents, Nootropic
- Nootropics
- Cognitive Enhancers
- Enhancers, Cognitive
- Nootropic Drugs
- Drugs, Nootropic
|
Below are MeSH descriptors whose meaning is more general than "Nootropic Agents".
Below are MeSH descriptors whose meaning is more specific than "Nootropic Agents".
This graph shows the total number of publications written about "Nootropic Agents" by people in this website by year, and whether "Nootropic Agents" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 3 | 0 | 3 |
| 1999 | 4 | 0 | 4 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 4 | 2 | 6 |
| 2003 | 5 | 4 | 9 |
| 2004 | 5 | 1 | 6 |
| 2005 | 1 | 2 | 3 |
| 2006 | 4 | 5 | 9 |
| 2007 | 6 | 4 | 10 |
| 2008 | 2 | 2 | 4 |
| 2009 | 2 | 2 | 4 |
| 2010 | 5 | 2 | 7 |
| 2011 | 8 | 3 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 3 | 8 |
| 2014 | 6 | 5 | 11 |
| 2015 | 6 | 3 | 9 |
| 2016 | 5 | 2 | 7 |
| 2017 | 10 | 2 | 12 |
| 2018 | 3 | 0 | 3 |
| 2019 | 8 | 3 | 11 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Nootropic Agents" by people in Profiles.
-
MSK1 is required for the experience- and ampakine-dependent enhancement of spatial reference memory and reversal learning and for the induction of Arc and BDNF. Neuropharmacology. 2024 Dec 15; 261:110110.
-
Platelet factors attenuate inflammation and rescue cognition in ageing. Nature. 2023 Aug; 620(7976):1071-1079.
-
Neuroprotective effect of herbal extracts inhibiting soluble epoxide hydrolase (sEH) and cyclooxygenase (COX) against chemotherapy-induced cognitive impairment in mice. Biochem Biophys Res Commun. 2023 07 30; 667:64-72.
-
Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 01 05; 388(1):9-21.
-
Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity? JAMA Intern Med. 2021 10 01; 181(10):1278-1280.
-
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Neuropsychopharmacology. 2021 09; 46(10):1788-1801.
-
Small molecule cognitive enhancer reverses age-related memory decline in mice. Elife. 2020 12 01; 9.
-
Presence of Piracetam in Cognitive Enhancement Dietary Supplements. JAMA Intern Med. 2020 03 01; 180(3):458-459.
-
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities. J Alzheimers Dis. 2020; 76(2):579-589.
-
Dopamine and norepinephrine transporter inhibition for long-term fear memory enhancement. Behav Brain Res. 2020 01 27; 378:112266.